Want to see AXSM full AI Analyst Report?
AXSM Stock Chart & Stats
$205.48
-$0.53(-0.22%)
At close: 4:00 PM EDT
$205.48
-$0.53(-0.22%)
Day’s Range― - ―
52-Week Range$112.90 - $260.19
Previous CloseN/A
Volume461.99K
Average Volume (3M)629.67K
Market Cap
$11.56B
Enterprise Value$12.58K
Total Cash (Recent Filing)$319.85M
Total Debt (Recent Filing)$219.21M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Nov 09, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding52,380,817
10 Day Avg. Volume533,419
30 Day Avg. Volume629,669
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)102.90
Price to Sales (P/S)14.23
P/FCF Ratio-96.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$291.00Price Target Upside41.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.67
Revenue Forecast (FY)$966.25M
Bulls Say, Bears Say
Bulls Say
Strong Commercial Revenue GrowthRapid growth across marketed products demonstrates expanding commercial adoption and improving scale. AUVELITY led momentum while SUNOSI and SYMBRAVO also contributed, creating a broader revenue base that can support investment in sales execution and the pipeline over the next several quarters.
High Gross Margin ProfileThe very high gross margin indicates that marketed products generate substantial value after direct product costs. If revenue expansion continues, this economics profile provides meaningful potential for incremental contribution, reinvestment, and operating leverage as commercialization expenses become more established.
Broad Late-stage CNS PipelineRegulatory progress on AXS-12 and multiple late-stage programs give Axsome several opportunities to extend its CNS franchise beyond current products. Potential filings through 2030 could diversify future revenue sources and support a durable pipeline-driven competitive position.
Bears Say
Persistent Operating LossesAxsome has achieved commercial scale but remains materially unprofitable, showing that revenue growth has not yet covered operating expenses and development investment. Continued losses reduce internally generated capital and make the path to durable earnings dependent on further growth and operating leverage.
Negative Cash GenerationNegative operating and free cash flow means the business is still consuming cash to fund operations despite improving burn from prior years. Until cash generation turns sustainably positive, Axsome has less flexibility to finance commercialization and research solely from internally generated funds.
Elevated Leverage And Thin EquityDebt is high relative to the company’s equity base, increasing financial sensitivity while Axsome remains loss-making and cash-flow negative. This leverage can constrain capital allocation and leave less balance-sheet flexibility for pipeline investment or absorbing setbacks before profitability improves.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $112.90 and its highest was $260.19 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $11.56B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Nov 09, 2026 which is in 56 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Aug 10, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.892 by -$0.098.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -0.49.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 52,380,817 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.892. Following the earnings report the stock price went up 3.831%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Axsome Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$291.00 (41.62% Upside)
$291.00 (41.62% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 80%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 19.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
AXSM Company Deck
AXSM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum across Axsome’s commercial portfolio, with 46% revenue growth, accelerating AUVELITY demand, encouraging early Alzheimer’s disease agitation launch metrics, continued SYMBRAVO and SUNOSI prescription growth, improving payer coverage, and substantial pipeline progress. The company remains loss-making, reported higher SG&A and ongoing cash burn, and acknowledged that several Alzheimer’s disease agitation launch metrics are still early and limited. Overall, the highlights significantly outweighed the lowlights.View all AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$291.00
▲(41.62% Upside)
Technical Analysis
Ownership Overview
15.08% Insiders
24.67% Mutual Funds
19.30% Other Institutional Investors
27.90% Public Companies and Individual Investors